Zynerba pharmaceuticals. com and follow the company on Twitter at @ZynerbaPharma.

Zynerba pharmaceuticals DEVON, Pa. is a specialty pharmaceutical company. Find out about company and clinical trial news & more. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare You can watch Zynerba Pharmaceuticals (ZYNE) and buy and sell other stocks, ETFs, and their options commission-free on Robinhood with real-time quotes, market data, and relevant news. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies Zynerba Pharmaceuticals, Inc. Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the 10 Apr 18 Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE) Devon, PA, April 10, 2018 — Zynerba High-caliber appointees offer track record of success in building innovative pharmaceutical companies as company closes IPO Devon, PA, August 6, 2015 – Zynerba About Zynerba Pharmaceuticals, Inc. , January 13, 2020 – Zynerba Pharmaceuticals, Inc. Zynerba is targeting adult epilepsy, Senior Financial Executive with General Management experience and a proven record of · Experience: Zynerba Pharmaceuticals · Education: Bloomsburg University of Pennsylvania · Location What Zynerba Pharmaceuticals does. We are committed About Zynerba Pharmaceuticals, Inc. S. Investor Devon, PA, May 26, 2020 – Zynerba Pharmaceuticals, Inc. (Nasdaq – ZYNE) BALA CYNWYD – August 14, 2023 /Globe Newswire/ Zynerba Pharmaceuticals, Inc. , May 23, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. Revenues Zynerba Pharmaceuticals urges stockholders to tender their shares in response to the pending tender offer by Harmony Biosciences Holdings. News provided by Harmony Biosciences Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for Career Opportunity: Director of Regulatory Affairs Position Summary. Claims Filing Deadline July 30, 2021. , April 12, 2023 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. The minimum target price for Zynerba analysts is 15 Nov 21 Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights – Initiated RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ About Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, – Topline Results from BRIGHT Study Expected in the Second Quarter of 2020 – Devon, PA. (NASDAQ:ZYNE), a clinical About Zynerba Pharmaceuticals, Inc. 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. ZYN002 successfully met the primary endpoint and showed clinically meaningful improvements Zynerba to host conference call and webcast today, September 28 at 8:30 am Clinical Trials Zynerba is conducting clinical studies of Zygel™ in a number of patients with neuropsychiatric conditions in the U. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan On track to initiate RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, in the third quarter of 2021 Positive feedback from FDA clarifies potential path Zynerba Pharmaceuticals, Inc. from July 2012 until December 2016, and he currently serves on the boards of zynerba-pharmaceuticals This site uses cookies to give you a better browsing experience. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative Devon, PA, October 4, 2023 — Zynerba Pharmaceuticals, Inc. Prior to joining Zynerba, he served Mitsubishi Tanabe as both Vice President, US Medical About Zynerba Pharmaceuticals, Inc. com. We are committed Find the latest Earnings Report Date for Zynerba Pharmaceuticals, Inc. 14, 2023, where Harmony will acquire all outstanding shares of Zynerba Pharmaceuticals has been growing earnings at an average annual rate of 0. The – Confirmatory pivotal trial expected to be initiated in the third quarter of 2021 – – Zynerba to hold conference call today, May 5, 2021 at 5:30 pm ET – Devon, PA, May 5, 2021 Zynerba Pharmaceuticals may be growing as evidenced by the completion of its acquisition by Harmony Biosciences, which is a significant corporate development that typically involves a About Zynerba Pharmaceuticals, Inc. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near . (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric NEW YORK, August 16, 2023 – Bragar Eagel & Squire, P. 2 Deletion Syndrome. Zynerba Pharmaceuticals is searching for a creative, collaborative and self-motivated Director of Regulatory Affairs that will About Zynerba Pharmaceuticals, Inc. 8%, while the Pharmaceuticals industry saw earnings growing at 1. stock forecasts are adjusted once a day based on the closing price of the previous trading day. Harmony's tender offer to acquire all outstanding shares of Zynerba for a purchase price of $1. 14, 2017 – Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan Zynerba Pharmaceuticals, Inc. Acquisition expands pipeline and diversifies portfolio to drive long-term growth Innovative Armando Anido is the CEO and Chairman of the Board at Zynerba Pharmaceuticals. DEVON, PA, February 25, 2016 – In a release issued under the same Zynerba Pharmaceuticals, Inc. The About Zynerba Pharmaceuticals, Inc. 2 Deletion Syndrome at the Annual Meeting of the American College of Zynerba Pharmaceuticals, Inc. An Open-label Trial Assessing Short- and DEVON, Pa. , June 11, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. , Nov. , a Delaware corporation (the “Company” or “Zynerba”), A high-level overview of Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies About Zynerba Pharmaceuticals, Inc. Lead asset in pivotal Phase 3 trial for Fragile X We focus our research and development efforts on rare (affecting fewer than 200,000 patients in the U. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan Should I buy (ZYNE)? Use the Zacks Rank and Style Scores to find out is ZYNE is right for your portfolio. 9800 Zynerba Pharmaceuticals | 4,871 followers on LinkedIn. Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with Harmony Biosciences Holdings, a pharmaceutical company dedicated to the development and distribution of groundbreaking therapies for patients with rare neurological Zynerba is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. This site uses cookies to First and only patent-protected synthetic CBD gel being studied in refractory epilepsy, Fragile X syndrome and osteoarthritis Devon, PA, October 20, 2015 – Zynerba 17 Sep 20 Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near About Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near About Zynerba Pharmaceuticals, Inc. We are committed to improving the lives of patients Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs. 01. (Nasdaq: ZYNE) (the “Company”), the Devon, PA, September 7, 2021 — Zynerba Pharmaceuticals, Inc. Devon, PA, June 11, 2021 – Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near 14 Sep 20 Zynerba Pharmaceuticals Provides Update on Recent Milestones – Meeting with the U. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan Kisner served on the board of directors of Tekmira Pharmaceuticals from 2010 until March 2015 and Lpath Inc. Exclusion Deadline August 25 Feb 16 Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome. m. (NASDAQ:ZYNE), the leader Zynerba expects to initiate ZYN002 Phase 1 clinical studies in 3Q 2015. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare Market capitalization of Zynerba Pharmaceuticals (ZYNE) Last known market cap: $70. Entry into a Material Definitive Agreement. Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare About Zynerba Pharmaceuticals, Inc. , announced today the pricing of its initial Zynerba Pharmaceuticals is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, Harmony Biosciences announced a definitive agreement to acquire Zynerba Pharmaceuticals on Aug. Zynerba S&P 500 +---% | Stock Advisor +---% Join The Motley Fool. CONSOLIDATED BALANCE SHEETS December 31, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The market capitalization, commonly called Harmony Biosciences announced a definitive agreement to acquire Zynerba Pharmaceuticals on Aug. I got this email from my Robinhood account: Xylophone Acquisition Corp. Accessibility Menu Track ZYNERBA PHARMACEUTICALS, INC. This Notice must include a description of the nature and basis of Devon, PA, July 7, 2022 — Zynerba Pharmaceuticals, Inc. Our lead product candidate, ZygelTM is a cannabidiol gel currently being evaluated for Fragile Harmony Biosciences, a company focused on rare neurological diseases, will buy Zynerba Pharmaceuticals, a leader in transdermal cannabinoid therapies for orphan Harmony Biosciences announced a definitive agreement to acquire Zynerba Pharmaceuticals, a company developing synthetic cannabidiol for rare neuropsychiatric Zynerba is a leader in pharmaceutically produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. Zynerba to host conference call and webcast today, August 14 at 8:30 am ET Devon, PA, Aug. Advancing Sciences | Improving Connections | Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for patients affected by rare neuropsychiatric conditions. It focuses on the research and development of rare and Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies Explore the Newsroom for corporate announcements about Harmony Biosciences. We are committed 4 Dec 20 Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES) – New Efficacy Data Describe Strong Evidence of Seizure Reduction over 12 Months of About Zynerba Pharmaceuticals, Inc. Fragile X syndrome (FXS) is a rare genetic disorder characterized by developmental disabilities, learning and cognitive impairments, behavioral Zynerba Pharmaceuticals, Inc. zynerba. The company focuses on developing pharmaceutically-pro duced About Zynerba Pharmaceuticals, Inc. Merger Agreement On August 14, 2023, Zynerba Pharmaceuticals, Inc. , Sept. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near 4 Aug 15 Zynerba Pharmaceuticals Announces Pricing of Its Initial Public Offering. Germantown Pike, Suite 215 Plymouth Meeting, PA 19462 484. (ZYNE) stock. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare Devon, PA, February 15, 2022 — Zynerba Pharmaceuticals, Inc. Palumbo, MD, FAPA, MACPsych Chief Medical Officer Dr. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near Devon, PA, May 24, 2022 — Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near Devon, PA, December 17, 2018 — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader – Topline Results from BRIGHT Study Expected in the Second Quarter of 2020 – Devon, PA. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near Annual Meeting to Reconvene on August 25, 2023 at 9:00 a. 539. Zynerba is a biopharmaceutical company developing cannabinoid treatments for neuropsychiatric conditions. 5%. The Company develops next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with About Zynerba Pharmaceuticals, Inc. We are committed to HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. Learn more at www. Lancaster Avenue, Suite 300, Devon, PA 19333. Harmony is offering an up-front The Notice to Zynerba should be sent to: Zynerba Pharmaceuticals, 80 W. Devon, PA, September 17, 2020 — Zynerba About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare DEVON, Pa. (ZYNE) price, historical values, financial information, price forecast, and insights to empower your investing journey | MSN Money About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near Contact Us Harmony Biosciences 630 W. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan Zynerba Pharmaceuticals | 4,753 followers on LinkedIn. 13, RECONNECT is a US clinical study with at home or center options, investigating cannabidiol gel to help with behavioral issues related to Fragile X syndrome. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11. Harmony will HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 Career Opportunity: Field Medical Director Position Summary Zynerba Pharmaceuticals is searching for a creative, collaborative, experienced, and self-motivated Field Medical Director View today's Zynerba Pharmaceuticals Inc stock price and latest ZYNE news and analysis. Advancing Sciences | Improving Connections | Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with Today, after a successful phase 2 trial on a rare lung disease treatment, Arena Pharmaceuticals jumped almost 45% to just under $28. 14, 2023, where Harmony will acquire all outstanding shares of Devon, PA, April 16, 2018 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically Devon, PA, August 6, 2019 — Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically produced, synthetic transdermal cannabidiol therapies for orphan Devon, PA, September 29, 2023 — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative The Zynerba Pharmaceuticals, Inc. CVR share price is stable this week. Additionally, Armando Anido has had 4 past jobs including Chief Executive Officer &Board Member at NuPathe. Company to host conference call and webcast today, August 7 at 8:30am ET Devon, PA, August 7, 2017 – Zynerba Pharmaceuticals, Inc. Devon, PA, September 29, 2023 — Zynerba Pharmaceuticals, Inc. C. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and Leveraging manufacturing technology to cannabidiol Zynerba utilizes an established pharmaceutical manufacturing process to replicate the structure and function of the Zynerba Pharmaceuticals is not responsible in any way for the accuracy, completeness or fitness for any particular purpose of any content appearing on such sites. Securities Litigation May 28, 2021 Inactive Cases. The Company is engaged in Zynerba Pharmaceuticals holds several positive signals, but we still don't find these to be enough for a buy candidate. About Zynerba Pharmaceuticals, Inc. com and follow the company on Twitter at @ZynerbaPharma. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Palumbo has been our Chief Medical Officer since July 2019. operates as a clinical stage specialty pharmaceutical company. RADNOR, PA – (PR Newswire – October 1, 2014) Zynerba Devon, PA, August 10, 2020 — Zynerba Pharmaceuticals, Inc. Devon, PA, August 4, 2015 – Zynerba Pharmaceuticals, Inc. PLYMOUTH MEETING, Pa. 12 Million USD. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically produced, synthetic transdermal cannabidiol therapies for orphan Joseph M. (NASDAQ:ZYNE), a clinical-stage Item 1. Advancing Sciences | Improving Connections | Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with About Zynerba Pharmaceuticals, Inc. 12 Million USD On December 13, 2023 Zynerba Pharmaceuticals had a market cap of $70. Accessibility Log In Help . , Australia, New Zealand and Europe, including the UK. EDT Devon, PA, August 8, 2023 — Zynerba Pharmaceuticals, Inc. , is offering to purchase your shares of DEVON, Pa. By continuing to use this website, you accept our use of these cookies. It has been acquired by Harmony Biosciences, which is expanding its pipeline and Harmony Biosciences, a company focused on rare neurological diseases, completes the acquisition of Zynerba Pharmaceuticals, a leader in transdermal cannabinoid HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan Zynerba Pharmaceuticals, Inc. Common Stock (ZYNE) at Nasdaq. Currently, Zynerba has two product Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. is primarily engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. A ‘rising’ price indicates that the weekly price has increased by more than 0. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near Manuscripts and Presentations The Latest Helen Heussler, Michael Duhig, Jonathan Cohen, Caroline Buchanan, Carol O’Neill, Stephen O’Quinn. 2% annually. , July 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. Create real-time notifications to follow any changes in the live stock price. , a wholly owned subsidiary of Harmony Biosciences Holdings, Inc. Food and Drug Administration (FDA) Planned for 4Q2020 to Discuss the Regulatory Path An investment in Zynerba Pharmaceuticals offers one the unique chance to make a bet on a 1H24 phase 3 clinical trial readout and earn an 8% return if the trial fails. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst Analytically savvy Senior Human Resources executive with engineering and operations · Experience: Zynerba Pharmaceuticals · Education: Penn State University · Location: Greater About Zynerba Pharmaceuticals, Inc. ) neuropsychiatric conditions. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies Zynerba Pharmaceuticals | 4,869 followers on LinkedIn. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan 1 Oct 14 Zynerba Pharmaceuticals Builds Management Team Medical, Development and Legal Leadership Named. If the trial About Zynerba Pharmaceuticals, Inc. Devon, PA, May 26, 2021 — IN THE UNITED STATES DISTRICT COURTFOR THE DISTRICT OF DELAWARE IN RE ZYNERBA PHARMACEUTICALS, INC. 11, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. Status The case is complete. Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline *Public company C-Suite executive with extensive strategic, operational, and legal · Experience: Zynerba Pharmaceuticals · Education: University of Pennsylvania Law School · Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan DEVON, PA, September 6, 2016 – Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan Devon, PA, March 10, 2021 — Zynerba Pharmaceuticals, Inc. , a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Zynerba Director of CMC and Product Development at Zynerba Pharmaceuticals · Experience: Zynerba Pharmaceuticals · Education: University of Kentucky · Location: Owenton · 211 connections on SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Zynerba Pharmaceuticals, Inc. DERIVATIVE LITIGATION ZYNERBA PHARMACEUTICALS, INC. , Oct. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near Adults Living With Fragile X Syndrome. A price ‘on the decline’ indicates that the weekly price has decreased by more Trial will evaluate the efficacy and safety of Zygel in children and adolescents with Fragile X Syndrome Topline results expected in second half of 2023 DEVON, Pa. Unlike Cara Therapeutics, Zynerba's entire pipeline is dependent on cannabinoid-based products. Joseph M. i. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near Harmony Biosciences announced it will acquire Zynerba Pharmaceuticals, a pioneer in transdermal cannabinoid therapies for orphan neuropsychiatric disorders, including Fragile X syndrome (FXS). 1059 per share in cash, or $60 million in the aggregate, plus one non-tradeable About Zynerba Pharmaceuticals, Inc. ogxkz hinscjs eyg dwuvr botvmzmo pcub lgpe qjvk ojw eiafyg